SCOTTSDALE, Ariz., July 26, 2018 /PRNewswire-PRWeb/ -- Previously only available with a prescription, low light laser therapy (LLLT) is now available over the counter (OTC). Emerging hair-regrowth company illumiflow® has announced the first FDA-cleared OTC laser cap, proven safe and clinically effective for men and women.
The illumiflow cap uses LLLT to stimulate the scalp at a cellular level. Although not a new innovation, the use of LLLT to treat hair loss has only recently become widespread.
This type of light therapy has its roots in the late 1960s and early 1970s. Hungarian physician and surgeon Endre Mester first discovered the healing potential of low-level lasers while experimenting on mice, and published his findings in multiple peer reviewed journals, including Lasers in Surgery and Medicine, and the American Journal of Surgery. More recently, modern publications such as the Laser Review have suggested that LLLT is effective in reversing hair loss caused by androgenetic alopecia and other disorders.
LLLT works by inhibiting 5-alpha Reductase, the enzyme responsible for converting testosterone into the hair loss hormone known as dihydrotestosterone (DHT). It also encourages the activation of the essential shock protein HSP27, and the increase of blood flow to the scalp.
The founder of illumiflow has a unique connection to its customer base: he, too, has overcome hair loss. While fighting his own battle with androgenetic alopecia, he unwittingly found a safe and cost-effective solution in LLLT. Thus, illumiflow has become the first hair-regrowth company to usher in a dramatic change in the way hair loss is treated. By taking all required steps for FDA 510(k) clearance, thoroughly testing the product and proving it to emit light at a safe and effective range of the spectrum, illumiflow differentiated itself from other LLLT products on the market.
Not only is the illumiflow laser cap is the first available to buy OTC for both men and women, it has reduced the cost to consumers by about three times what patients might expect to pay for a doctor's prescription, while insuring the same level of medical effectiveness.
Perhaps the most unique feature of the illumiflow cap is that it emits lights from 272 diodes for complete scalp coverage. According to dermatologists at Skin Renaissance Clinic, this number allows for optimal cellular regeneration.
"We've been using this technology for some time and we think it's really, really effective," said Dr. Celia Brown, M.D. "Our patients like it, I'm using it, I have seen some improvement in my hair density as well as my staff. So, we think it's an effective treatment. We think this Illumiflow device has excellent technology behind it and it really does seem to work for us."
She described illumiflow as "a growth lamp for your hair."
The illumiflow laser cap is reportedly safe to use in conjunction with most other hair growth treatments, such as Rogaine or Finasteride. In fact, LLLT has few, if any contraindications— in other words, it should not interfere in any way with any other scalp or hair medication.
The cap is touted as simple and convenient, with a recommended maintenance schedule of 3x per week for just 15-30 minutes per session.
Using this protocol, users can reportedly expect results in 4-6 months.
Readers interested in more information can visit the illumiflow site at http://www.illumiflow.com